{"gene":"APOA1","run_date":"2026-06-09T22:02:43","timeline":{"discoveries":[{"year":2018,"finding":"APOA1 on nascent discoidal HDL adopts two distinct helical registries (5/5 and 5/2) via a thumbwheel-like rotation mechanism. Engineered disulfide bonds locking APOA1 in the 5/2 registry impaired LCAT cholesteryl esterification activity without affecting LCAT binding or cholesterol efflux, indicating that full LCAT activation requires a hybrid epitope composed of helices 5-7 on one APOA1 molecule and helices 3-4 on the other.","method":"Cysteine mutagenesis to engineer disulfide-locked discoidal HDL particles, LCAT activity assay, cholesterol efflux assay, chemical cross-linking","journal":"Journal of lipid research","confidence":"High","confidence_rationale":"Tier 1 / Strong — reconstitution with mutagenesis, disulfide-locking, enzymatic activity assay, and cross-linking in a single rigorous study with multiple orthogonal methods","pmids":["29773713"],"is_preprint":false},{"year":2023,"finding":"In small HDL particles, the C-termini of the two antiparallel APOA1 molecules are 'flipped' off the lipid surface, enabling engagement with ABCA1 transporter and promoting cholesterol efflux. In larger HDL particles, C-termini form a helical bundle adhering to the lipid surface, preventing productive ABCA1 interaction. Conversion of small HDL to larger particles by LCAT markedly inhibited cholesterol efflux capacity.","method":"Tandem mass spectrometric analysis of chemically cross-linked peptides, molecular dynamics simulations, reconstituted HDL model system, cholesterol efflux capacity assay in macrophages, studies in LCAT-deficient subjects, calibrated ion mobility analysis","journal":"Circulation","confidence":"High","confidence_rationale":"Tier 1 / Strong — multiple orthogonal methods including MS cross-linking, MD simulation, reconstituted HDL, and human disease model with mechanistic validation","pmids":["38018436"],"is_preprint":false},{"year":2021,"finding":"TRIM15 E3 ubiquitin ligase interacts with APOA1 through its PRY/SPRY domain and promotes APOA1 polyubiquitination via its RING domain, leading to APOA1 degradation. APOA1 degradation enhances lipid anabolism and promotes lipid droplet accumulation in pancreatic cancer cells, and TRIM15 promotes PDAC metastasis via the APOA1-LDLR axis.","method":"Mass spectrometry identification of TRIM15-binding partners, co-immunoprecipitation, domain-deletion mutagenesis, ubiquitination assay, siRNA knockdown with invasion/migration assays, lipid droplet staining","journal":"Biochimica et biophysica acta. Molecular basis of disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP, domain mutagenesis, and ubiquitination assay from single lab with multiple methods","pmids":["34311082"],"is_preprint":false},{"year":2013,"finding":"In vivo tissue cholesterol efflux is reduced by ~19% in carriers of the L202P mutation in APOA1 (mean HDL-c 20 mg/dL vs. 54 mg/dL in controls), demonstrating that APOA1 contributes to efflux of tissue cholesterol in humans as part of reverse cholesterol transport. Fecal sterol excretion did not differ significantly, suggesting non-HDL pathways also contribute to reverse cholesterol transport.","method":"13C2-cholesterol isotope tracer infusion in vivo, three-compartment SAAM-II pharmacokinetic modeling, fecal 13C recovery measurement in APOA1 L202P mutation carriers vs. controls","journal":"Journal of lipid research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct in vivo isotope tracer study in human mutation carriers with compartmental modeling, single lab","pmids":["23650622"],"is_preprint":false},{"year":2020,"finding":"Recombinant ApoA-1 injected in vivo improves glucose tolerance and increases glucose clearance into skeletal muscle (+50%) and heart muscle (+270%) independently of AMPKα2 kinase activity. ApoA-1 also increased glucose-stimulated insulin secretion. ApoA-1 failed to increase glucose uptake in isolated skeletal muscles ex vivo, indicating that systemic effects beyond direct muscle action are required.","method":"Intravenous injection of recombinant human ApoA-1 in high-fat diet-fed wild-type and AMPKα2 kinase-dead mice, glucose tolerance test, 2-deoxyglucose uptake measurement in vivo, epinephrine/propranolol-induced insulin secretion blockade, ex vivo isolated muscle glucose uptake assay","journal":"Molecular metabolism","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — clean genetic KO model (AMPKα2 kinase-dead) with defined metabolic phenotype and multiple conditions tested, single lab","pmids":["32244181"],"is_preprint":false},{"year":2021,"finding":"ApoA1-mediated lipid raft depletion inhibits DENV (dengue virus) attachment to cell surfaces. ApoA1 neutralizes NS1-induced cell activation and prevents NS1-mediated enhancement of DENV infection. The ApoA1 mimetic peptide 4F similarly depletes lipid rafts to control DENV infection.","method":"Cell-based infection assay, lipid raft staining/quantification, NS1 protein treatment of cells, ApoA1 co-treatment, peptide 4F treatment, flow cytometry","journal":"Journal of virology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct cell-based mechanistic experiments with protein-virus interaction and multiple readouts from single lab","pmids":["33827950"],"is_preprint":false},{"year":2016,"finding":"In an in vitro BBB model, rApoA1 complexed to Aβ1-40 did not influence Aβ1-40 efflux from the basolateral (brain) compartment, but rApoA1 present in the apical (blood) compartment mobilized Aβ1-40 from the basolateral side. rApoA1 crossed the monolayer (blood-to-brain direction) through a mechanism involving the LDL receptor-related protein family, and rApoA1 trafficking was restricted when bound to Aβ peptide.","method":"Primary cerebral endothelial cell Transwell BBB model, fluorescently labeled Aβ1-40 transport assay, LRP family inhibitor treatment, compartment-specific protein addition","journal":"Journal of Alzheimer's disease : JAD","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, in vitro model only, no molecular mechanistic follow-up beyond transport measurement","pmids":["27232214"],"is_preprint":false},{"year":2015,"finding":"SAXS structural analysis showed that in discoidal ApoA1-POPC-cholesterol particles, the N-terminal domain of full-length ApoA1 is an integrated part of the protein belt (not a separate globular domain) that stabilizes the particles. Upon cholesterol incorporation, the N-terminal domain allows bilayer thickness to increase while maintaining a flat bilayer, in contrast to N-terminally truncated ApoA1 (nanodisc) which forms a less favorable lens shape.","method":"Small-angle X-ray scattering (SAXS), molecular-constrained data modeling, comparison of full-length vs. N-terminally truncated ApoA1 particles with varying cholesterol content","journal":"Biophysical journal","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — SAXS structural analysis with molecular modeling and comparative functional context, single lab","pmids":["26200866"],"is_preprint":false},{"year":2020,"finding":"HDL and ApoA-1 reduce glucagon expression and secretion from pancreatic α-cells in vitro through binding to receptor SCARB-1 (SR-BI) and activating the PI3K/Akt/FoxO1 signaling cascade. Pretreatment with Akt inhibitor, PI3K inhibitor, or SCARB-1 inhibitor BLT-1 restored α-cell response to low glucose, demonstrating dependence on this pathway.","method":"In vitro αTC1 cell treatment with HDL or ApoA-1, glucagon secretion and expression assays, phosphorylation assays for Akt and FoxO1, pharmacological inhibitors (Akt inhibitor VIII, LY294002, BLT-1), in vivo mouse ApoA-1 injection with insulin-induced hypoglycemia","journal":"Arteriosclerosis, thrombosis, and vascular biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple pathway inhibitors used in cell-based assay plus in vivo validation, single lab","pmids":["33086869"],"is_preprint":false},{"year":2016,"finding":"ApoA1 activates the ERK pathway and promotes actin polymerization in a neuroblastoma injury model, contributing to wound healing after neuronal injury. ApoA1 expression increases as a delayed response to neuronal injury, and ApoA1 treatment accelerated scratch wound closure after an initial lag phase.","method":"Neuroblastoma scratch wound assay, ApoA1 treatment, ERK pathway activation measurement, actin polymerization assay, spinal cord injury model","journal":"Molecular and cellular biochemistry","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, limited mechanistic detail in abstract, single cell-type model","pmids":["27734225"],"is_preprint":false},{"year":2018,"finding":"ApoA-1 treatment of hepatocytes attenuated steatosis and accelerated proliferation, and in a mouse hepatectomy model promoted liver regeneration at day 2 post-surgery. ApoA-1 treatment increased expression of PGC-1α and its target genes Tfam, Ucp2, and SDHB, suggesting a mechanism through regulation of mitochondrial function.","method":"Rat liver transplantation model (small-for-size fatty graft), mouse hepatectomy model in vivo, in vitro hepatocyte culture with ApoA-1 treatment, gene expression analysis (PGC-1α, Tfam, Ucp2, SDHB), steatosis quantification","journal":"Life sciences","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, mechanistic pathway identified by expression analysis only without direct functional validation of PGC-1α pathway dependence","pmids":["30473024"],"is_preprint":false},{"year":2016,"finding":"Heparin interacts with both ApoA1 and SAA (serum amyloid A) on HDL isolated from inflamed mice, forming complex aggregates. Mass spectrometry analysis of chemically crosslinked HDL-SAA particles detected multiple crosslinks between ApoA1 and SAA, indicating close proximity (within 25 Å) on the HDL surface, providing a structural basis for simultaneous heparin binding.","method":"Gel electrophoresis of heparin-HDL complexes, chemical crosslinking, mass spectrometry peptide mapping of crosslinked ApoA1-SAA interactions","journal":"Biochemical and biophysical research communications","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, crosslinking-MS provides proximity data but no direct functional consequence tested","pmids":["27105909"],"is_preprint":false},{"year":2013,"finding":"ABCA1-dependent secretion of vitamin E (tocopherols) from Caco-2 intestinal monolayers is mediated in part via ApoA1 as acceptor. The ABCA1/ApoA1 pathway demonstrated vitamer selectivity, with α- and γ-tocopherol secreted more efficiently than δ-tocopherol. Liver X receptor agonist T0901317 induced ABCA1 expression and enhanced tocopherol secretion to ApoA1.","method":"Polarized Caco-2 monolayer assay, ABCA1 protein expression (Western blot), LXR agonist treatment, MTP inhibitor treatment, tocopherol secretion quantification with three tocopherol forms simultaneously","journal":"The Journal of nutrition","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mechanistic dissection using pharmacological tools with multiple tocopherol forms and ABCA1 expression data, single lab","pmids":["23946344"],"is_preprint":false},{"year":2014,"finding":"Tissue-specific DNA methylation of the APOA1/C3/A4/A5 gene cluster inversely correlates with tissue-specific expression. APOA1 promoter is less methylated in liver than other tissues. Demethylation of intestinal TC7/Caco-2 cells with 5-Aza-2'-deoxycytidine reduced methylation of APOA1/C3/A4/A5 by 24-37% and induced re-expression of APOA1 mRNA (up to 600% increase), demonstrating that DNA methylation controls liver-specific APOA1 expression.","method":"Infinium HumanMethylation450 BeadChip array across multiple tissues, bisulfite PCR and pyrosequencing, 5-Aza-2'-deoxycytidine demethylation treatment of intestinal cells, RT-qPCR for gene re-expression","journal":"Atherosclerosis","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genome-wide methylation profiling validated by bisulfite sequencing, combined with functional demethylation rescue experiment, single lab","pmids":["25463085"],"is_preprint":false},{"year":2024,"finding":"FOXM1 transcription factor represses METTL3 transcription by binding to the METTL3 promoter (confirmed by ChIP), which reduces m6A methylation of APOA1 mRNA, thereby decreasing YTHDF2-mediated APOA1 mRNA degradation and increasing APOA1 expression. Elevated APOA1 in hypoxia-induced scleral fibroblasts promotes myofibroblast transdifferentiation, reduced collagen production, and apoptosis. Knockdown of APOA1 or FOXM1 reversed these hypoxia-induced effects.","method":"Chromatin immunoprecipitation (ChIP) for FOXM1 on METTL3 promoter, methylated RNA immunoprecipitation (Me-RIP) for m6A on APOA1 mRNA, PAR-CLIP for METTL3-APOA1 binding, siRNA knockdown, Western blot, RT-qPCR, cell proliferation/apoptosis assays","journal":"Investigative ophthalmology & visual science","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal epigenetic methods (ChIP, Me-RIP, PAR-CLIP) with functional rescue experiments, single lab","pmids":["38190128"],"is_preprint":false},{"year":2005,"finding":"Denaturation and fusion kinetics of discoidal HDL particles show that kinetic stability rank order is apoA-1 > apoA-2 > apoC-1, correlating with protein size. Protein unfolding triggers HDL fusion, leading to lipid vesicle formation and dissociation of monomolecular lipid-poor protein. Two kinetic phases with distinct activation energies (Ea,slow = 60 kcal/mol, Ea,fast = 22 kcal/mol) were identified for apoA-2 disks.","method":"Circular dichroism melting, light scattering, differential scanning calorimetry, Arrhenius analysis, electron microscopy, gel electrophoresis; comparative analysis of apoA-1 vs apoA-2 vs apoC-1 disks","journal":"Biophysical journal","confidence":"Low","confidence_rationale":"Tier 3 / Weak — comparative biophysical study primarily focused on apoA-2; APOA1 data are comparative reference points, not the primary subject of mechanistic analysis","pmids":["15681655"],"is_preprint":false}],"current_model":"APOA1 is the major structural and functional protein of HDL that adopts anti-parallel helical ring configurations on discoidal HDL particles, with the two molecules capable of adopting distinct registries (5/5 vs 5/2) via a thumbwheel mechanism to activate LCAT; in small HDL particles the C-termini flip off the lipid surface to engage ABCA1 and drive cholesterol efflux, while on larger particles the C-termini form a helical bundle that prevents ABCA1 interaction; APOA1 mediates reverse cholesterol transport in vivo (established by isotope tracer studies in mutation carriers), activates glucagon suppression in pancreatic α-cells via SCARB-1/PI3K/Akt/FoxO1, promotes glucose uptake in muscle independently of AMPKα2, is subject to ubiquitin-mediated degradation by TRIM15, and its expression is regulated by tissue-specific DNA methylation and by the FOXM1-METTL3-m6A-YTHDF2 axis."},"narrative":{"mechanistic_narrative":"APOA1 is the principal structural and functional protein of HDL, organizing lipid particles and driving reverse cholesterol transport [PMID:29773713, PMID:23650622]. On nascent discoidal HDL the two antiparallel APOA1 molecules adopt distinct helical registries (5/5 and 5/2) interconverting via a thumbwheel-like rotation; full activation of LCAT-mediated cholesteryl esterification requires a hybrid epitope formed by helices 5–7 of one molecule and helices 3–4 of the other [PMID:29773713]. The integrated N-terminal domain functions as part of the protein belt that stabilizes the discoidal bilayer and accommodates cholesterol loading [PMID:26200866]. Particle size governs function: in small HDL the APOA1 C-termini flip off the lipid surface to engage the ABCA1 transporter and promote cholesterol efflux, whereas in larger particles the C-termini form a lipid-adherent helical bundle that prevents productive ABCA1 interaction, so LCAT-driven conversion of small to large HDL suppresses efflux capacity [PMID:38018436]. The ABCA1/APOA1 acceptor system also mediates selective tocopherol secretion from intestinal cells [PMID:23946344]. In humans, the APOA1 L202P mutation reduces in vivo tissue cholesterol efflux, confirming a causal contribution to reverse cholesterol transport [PMID:23650622]. Beyond lipid handling, APOA1 acts as a signaling ligand: it engages SCARB-1 to activate PI3K/Akt/FoxO1 and suppress glucagon in pancreatic α-cells [PMID:33086869] and improves systemic glucose tolerance and muscle glucose uptake independently of AMPKα2 [PMID:32244181]. APOA1 abundance is controlled both by tissue-specific promoter DNA methylation favoring hepatic expression [PMID:25463085] and by the FOXM1–METTL3–m6A–YTHDF2 axis governing mRNA stability [PMID:38190128], and the protein is targeted for polyubiquitination and degradation by the E3 ligase TRIM15 [PMID:34311082].","teleology":[{"year":2005,"claim":"Established the relative kinetic stability of APOA1 on discoidal particles and linked protein unfolding to HDL fusion and lipid-poor protein release, framing HDL remodeling as a kinetically governed process.","evidence":"Comparative biophysical analysis (CD melting, DSC, light scattering, EM) of apoA-1 vs apoA-2 vs apoC-1 disks","pmids":["15681655"],"confidence":"Low","gaps":["APOA1 served as a comparative reference, not the primary subject","No connection to physiological remodeling enzymes tested"]},{"year":2013,"claim":"Provided direct in vivo human evidence that APOA1 drives tissue cholesterol efflux, moving reverse cholesterol transport from inference to causal demonstration.","evidence":"13C-cholesterol isotope tracer infusion with compartmental modeling in APOA1 L202P mutation carriers vs controls","pmids":["23650622"],"confidence":"Medium","gaps":["Fecal sterol excretion unchanged, indicating non-HDL pathways contribute","Single mutation, single lab"]},{"year":2015,"claim":"Resolved the structural role of the APOA1 N-terminal domain, showing it is integrated into the lipid-binding belt rather than a separate globular module and enables stable cholesterol-loaded discs.","evidence":"SAXS with molecular modeling comparing full-length vs N-terminally truncated APOA1 particles at varying cholesterol","pmids":["26200866"],"confidence":"Medium","gaps":["No atomic-resolution structure","Does not address dynamics during enzymatic remodeling"]},{"year":2018,"claim":"Defined the conformational mechanism of LCAT activation, showing APOA1 toggles between helical registries and that a two-molecule hybrid epitope is required for esterification activity.","evidence":"Disulfide-locked discoidal HDL via cysteine mutagenesis, LCAT activity and efflux assays, chemical cross-linking","pmids":["29773713"],"confidence":"High","gaps":["Registry switching kinetics in native particles not measured","Triggers of the thumbwheel rotation in vivo unknown"]},{"year":2023,"claim":"Linked HDL particle size to cholesterol efflux capacity through C-terminal positioning, explaining why LCAT-driven particle enlargement suppresses ABCA1 engagement.","evidence":"Cross-linking MS, MD simulation, reconstituted HDL, macrophage efflux assays, LCAT-deficient human subjects","pmids":["38018436"],"confidence":"High","gaps":["Structure of the APOA1–ABCA1 contact not solved","Regulation of C-terminal flipping in vivo not defined"]},{"year":2013,"claim":"Showed the ABCA1/APOA1 acceptor pathway exports cargo beyond cholesterol, mediating vitamer-selective tocopherol secretion from intestinal cells.","evidence":"Polarized Caco-2 monolayer secretion assay with LXR agonist and MTP inhibitor, ABCA1 Western blot","pmids":["23946344"],"confidence":"Medium","gaps":["Molecular basis of vitamer selectivity unresolved","In vivo relevance not tested"]},{"year":2020,"claim":"Identified APOA1 as a glucose-homeostasis signaling ligand, suppressing glucagon via SCARB-1/PI3K/Akt/FoxO1 and enhancing muscle glucose uptake through systemic rather than direct mechanisms.","evidence":"αTC1 cell assays with pathway inhibitors plus in vivo mouse injection (glucagon study); recombinant ApoA-1 injection in HFD and AMPKα2 kinase-dead mice with 2-DG uptake (glucose study)","pmids":["33086869","32244181"],"confidence":"Medium","gaps":["Receptor mediating muscle effect not identified","Failure of ex vivo muscle uptake leaves systemic mediator undefined"]},{"year":2021,"claim":"Revealed post-translational control of APOA1 abundance, with TRIM15 binding via its PRY/SPRY domain and polyubiquitinating APOA1 via its RING domain to drive degradation and tumor lipid accumulation.","evidence":"MS interactor identification, reciprocal Co-IP, domain-deletion mutagenesis, ubiquitination assay, knockdown invasion assays in PDAC cells","pmids":["34311082"],"confidence":"Medium","gaps":["Ubiquitination sites on APOA1 not mapped","Single lab, cancer-context only"]},{"year":2014,"claim":"Established that tissue-specific DNA methylation of the APOA1/C3/A4/A5 cluster controls hepatic-restricted APOA1 expression.","evidence":"Genome-wide methylation array, bisulfite pyrosequencing, 5-Aza demethylation rescue with RT-qPCR re-expression","pmids":["25463085"],"confidence":"Medium","gaps":["Specific regulatory CpGs not functionally dissected","Trans-acting factors reading methylation not identified"]},{"year":2024,"claim":"Defined an epitranscriptomic regulatory axis in which FOXM1 represses METTL3 to lower APOA1 m6A marking, reducing YTHDF2-mediated mRNA decay and raising APOA1 with downstream effects on scleral fibroblast fate.","evidence":"ChIP, Me-RIP, PAR-CLIP, siRNA knockdown with rescue, RT-qPCR and apoptosis assays in hypoxic scleral fibroblasts","pmids":["38190128"],"confidence":"Medium","gaps":["m6A sites on APOA1 mRNA not precisely mapped","Generalizability beyond scleral fibroblasts untested"]},{"year":null,"claim":"How the registry/thumbwheel conformational cycle, C-terminal flipping, and size-dependent ABCA1 engagement are coordinated and regulated on native circulating HDL remains unresolved.","evidence":"","pmids":[],"confidence":"High","gaps":["No native high-resolution structure of the APOA1–ABCA1 complex","Physiological triggers of conformational switching unknown","Integration of transcriptional, epitranscriptomic, and degradation control into systemic lipid/glucose phenotypes not established"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0008289","term_label":"lipid binding","supporting_discovery_ids":[0,1,7]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[0,8]},{"term_id":"GO:0048018","term_label":"receptor ligand activity","supporting_discovery_ids":[8,4]},{"term_id":"GO:0005198","term_label":"structural molecule activity","supporting_discovery_ids":[1,7]}],"localization":[{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[0,1,3]}],"pathway":[{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[0,1,3,12]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[8,4]},{"term_id":"R-HSA-382551","term_label":"Transport of small molecules","supporting_discovery_ids":[1,12]}],"complexes":["HDL"],"partners":["LCAT","ABCA1","SCARB1","TRIM15","SAA"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P02647","full_name":"Apolipoprotein A-I","aliases":["Apolipoprotein A1"],"length_aa":267,"mass_kda":30.8,"function":"Participates in the reverse transport of cholesterol from tissues to the liver for excretion by promoting cholesterol efflux from tissues and by acting as a cofactor for the lecithin cholesterol acyltransferase (LCAT). As part of the SPAP complex, activates spermatozoa motility","subcellular_location":"Secreted","url":"https://www.uniprot.org/uniprotkb/P02647/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/APOA1","classification":"Not Classified","n_dependent_lines":2,"n_total_lines":1208,"dependency_fraction":0.0016556291390728477},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/APOA1","total_profiled":1310},"omim":[{"mim_id":"620657","title":"AMYLOIDOSIS, HEREDITARY SYSTEMIC 3; AMYLD3","url":"https://www.omim.org/entry/620657"},{"mim_id":"620112","title":"APOA1 ANTISENSE RNA, NONCODING; APOA1AS","url":"https://www.omim.org/entry/620112"},{"mim_id":"620058","title":"FAMILIAL APOLIPOPROTEIN GENE CLUSTER DELETION SYNDROME","url":"https://www.omim.org/entry/620058"},{"mim_id":"619836","title":"HYPOALPHALIPOPROTEINEMIA, PRIMARY, 2, INTERMEDIATE","url":"https://www.omim.org/entry/619836"},{"mim_id":"618882","title":"IMERSLUND-GRASBECK SYNDROME 2; IGS2","url":"https://www.omim.org/entry/618882"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Vesicles","reliability":"Approved"},{"location":"Cytosol","reliability":"Additional"}],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"liver","ntpm":20151.0}],"url":"https://www.proteinatlas.org/search/APOA1"},"hgnc":{"alias_symbol":[],"prev_symbol":[]},"alphafold":{"accession":"P02647","domains":[],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P02647","model_url":"https://alphafold.ebi.ac.uk/files/AF-P02647-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P02647-F1-predicted_aligned_error_v6.png","plddt_mean":73.56},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=APOA1","jax_strain_url":"https://www.jax.org/strain/search?query=APOA1"},"sequence":{"accession":"P02647","fasta_url":"https://rest.uniprot.org/uniprotkb/P02647.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P02647/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P02647"}},"corpus_meta":[{"pmid":"33591433","id":"PMC_33591433","title":"APOA1: a Protein with Multiple Therapeutic Functions.","date":"2021","source":"Current atherosclerosis reports","url":"https://pubmed.ncbi.nlm.nih.gov/33591433","citation_count":140,"is_preprint":false},{"pmid":"25249180","id":"PMC_25249180","title":"The discovery of I-BET726 (GSK1324726A), a potent tetrahydroquinoline ApoA1 up-regulator and selective BET bromodomain inhibitor.","date":"2014","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25249180","citation_count":138,"is_preprint":false},{"pmid":"15767855","id":"PMC_15767855","title":"The APOA1/C3/A4/A5 gene cluster, lipid metabolism and cardiovascular disease risk.","date":"2005","source":"Current opinion in lipidology","url":"https://pubmed.ncbi.nlm.nih.gov/15767855","citation_count":112,"is_preprint":false},{"pmid":"36063649","id":"PMC_36063649","title":"Leveraging knowledge of HDLs major protein ApoA1: Structure, function, mutations, and potential therapeutics.","date":"2022","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/36063649","citation_count":105,"is_preprint":false},{"pmid":"19324996","id":"PMC_19324996","title":"Hereditary apolipoprotein AI-associated amyloidosis in surgical pathology specimens: identification of three novel mutations in the APOA1 gene.","date":"2009","source":"The Journal of molecular diagnostics : JMD","url":"https://pubmed.ncbi.nlm.nih.gov/19324996","citation_count":93,"is_preprint":false},{"pmid":"14551155","id":"PMC_14551155","title":"Linkage and association between distinct variants of the APOA1/C3/A4/A5 gene cluster and familial combined hyperlipidemia.","date":"2003","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/14551155","citation_count":84,"is_preprint":false},{"pmid":"14962947","id":"PMC_14962947","title":"In-depth haplotype analysis of ABCA1 gene polymorphisms in relation to plasma ApoA1 levels and myocardial infarction.","date":"2004","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/14962947","citation_count":84,"is_preprint":false},{"pmid":"27183204","id":"PMC_27183204","title":"ApoA1 and ApoA1-specific self-antibodies in cardiovascular disease.","date":"2016","source":"Laboratory investigation; a journal of technical methods and pathology","url":"https://pubmed.ncbi.nlm.nih.gov/27183204","citation_count":77,"is_preprint":false},{"pmid":"2903847","id":"PMC_2903847","title":"DNA polymorphism haplotypes of the human apolipoprotein APOA1-APOC3-APOA4 gene cluster.","date":"1988","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/2903847","citation_count":70,"is_preprint":false},{"pmid":"29773713","id":"PMC_29773713","title":"A thumbwheel mechanism for APOA1 activation of LCAT activity in HDL.","date":"2018","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/29773713","citation_count":69,"is_preprint":false},{"pmid":"16130094","id":"PMC_16130094","title":"APOA1 polymorphism influences risk for early-onset nonfamiliar AD.","date":"2005","source":"Annals of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/16130094","citation_count":67,"is_preprint":false},{"pmid":"30941792","id":"PMC_30941792","title":"KCNQ1OT1, HIF1A-AS2 and APOA1-AS are promising novel biomarkers for diagnosis of coronary artery disease.","date":"2019","source":"Clinical and experimental pharmacology & physiology","url":"https://pubmed.ncbi.nlm.nih.gov/30941792","citation_count":53,"is_preprint":false},{"pmid":"20399916","id":"PMC_20399916","title":"Reduced plasma APOA1 level is associated with gastric tumor growth in MKN45 mouse xenograft model.","date":"2010","source":"Journal of proteomics","url":"https://pubmed.ncbi.nlm.nih.gov/20399916","citation_count":51,"is_preprint":false},{"pmid":"21875686","id":"PMC_21875686","title":"Increased risk of coronary artery disease in Caucasians with extremely low HDL cholesterol due to mutations in ABCA1, APOA1, and LCAT.","date":"2011","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/21875686","citation_count":51,"is_preprint":false},{"pmid":"27232214","id":"PMC_27232214","title":"Modulation of Amyloid-β1-40 Transport by ApoA1 and ApoJ Across an in vitro Model of the Blood-Brain Barrier.","date":"2016","source":"Journal of Alzheimer's disease : JAD","url":"https://pubmed.ncbi.nlm.nih.gov/27232214","citation_count":50,"is_preprint":false},{"pmid":"32456156","id":"PMC_32456156","title":"The Positive Side of the Alzheimer's Disease Amyloid Cross-Interactions: The Case of the Aβ 1-42 Peptide with Tau, TTR, CysC, and ApoA1.","date":"2020","source":"Molecules (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/32456156","citation_count":49,"is_preprint":false},{"pmid":"19592705","id":"PMC_19592705","title":"Effects of variations in the APOA1/C3/A4/A5 gene cluster on different parameters of postprandial lipid metabolism in healthy young men.","date":"2010","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/19592705","citation_count":48,"is_preprint":false},{"pmid":"26491253","id":"PMC_26491253","title":"Decreased expression of the APOA1-APOC3-APOA4 gene cluster is associated with risk of Alzheimer's disease.","date":"2015","source":"Drug design, development and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/26491253","citation_count":45,"is_preprint":false},{"pmid":"34311082","id":"PMC_34311082","title":"TRIM15 promotes the invasion and metastasis of pancreatic cancer cells by mediating APOA1 ubiquitination and degradation.","date":"2021","source":"Biochimica et biophysica acta. Molecular basis of disease","url":"https://pubmed.ncbi.nlm.nih.gov/34311082","citation_count":45,"is_preprint":false},{"pmid":"10889803","id":"PMC_10889803","title":"Genetic determinants of plasma lipid response to dietary intervention: the role of the APOA1/C3/A4 gene cluster and the APOE gene.","date":"2000","source":"The British journal of nutrition","url":"https://pubmed.ncbi.nlm.nih.gov/10889803","citation_count":44,"is_preprint":false},{"pmid":"15681655","id":"PMC_15681655","title":"Kinetic stabilization and fusion of apolipoprotein A-2:DMPC disks: comparison with apoA-1 and apoC-1.","date":"2005","source":"Biophysical journal","url":"https://pubmed.ncbi.nlm.nih.gov/15681655","citation_count":43,"is_preprint":false},{"pmid":"12556235","id":"PMC_12556235","title":"The study of APOA1, APOC3 and APOA4 variability in healthy ageing people reveals another paradox in the oldest old subjects.","date":"2003","source":"Annals of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/12556235","citation_count":42,"is_preprint":false},{"pmid":"21122859","id":"PMC_21122859","title":"Gene-nutrient interactions and gender may modulate the association between ApoA1 and ApoB gene polymorphisms and metabolic syndrome risk.","date":"2010","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/21122859","citation_count":41,"is_preprint":false},{"pmid":"19057464","id":"PMC_19057464","title":"Pharmacogenetic association of the APOA1/C3/A4/A5 gene cluster and lipid responses to fenofibrate: the genetics of lipid-lowering drugs and diet network study.","date":"2009","source":"Pharmacogenetics and genomics","url":"https://pubmed.ncbi.nlm.nih.gov/19057464","citation_count":40,"is_preprint":false},{"pmid":"15108119","id":"PMC_15108119","title":"The effects of scale: variation in the APOA1/C3/A4/A5 gene cluster.","date":"2004","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/15108119","citation_count":39,"is_preprint":false},{"pmid":"14636880","id":"PMC_14636880","title":"APOA1 related amyloidosis: a case report and literature review.","date":"2003","source":"Clinical biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/14636880","citation_count":38,"is_preprint":false},{"pmid":"24969553","id":"PMC_24969553","title":"Identification of ApoA1, HPX and POTEE genes by omic analysis in breast cancer.","date":"2014","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/24969553","citation_count":37,"is_preprint":false},{"pmid":"33827950","id":"PMC_33827950","title":"ApoA1 Neutralizes Proinflammatory Effects of Dengue Virus NS1 Protein and Modulates Viral Immune Evasion.","date":"2021","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/33827950","citation_count":35,"is_preprint":false},{"pmid":"26824674","id":"PMC_26824674","title":"Interactions of Environmental Factors and APOA1-APOC3-APOA4-APOA5 Gene Cluster Gene Polymorphisms with Metabolic Syndrome.","date":"2016","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26824674","citation_count":34,"is_preprint":false},{"pmid":"23209431","id":"PMC_23209431","title":"Population-based resequencing of APOA1 in 10,330 individuals: spectrum of genetic variation, phenotype, and comparison with extreme phenotype approach.","date":"2012","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/23209431","citation_count":34,"is_preprint":false},{"pmid":"21443680","id":"PMC_21443680","title":"Mutation in APOA1 predicts increased risk of ischaemic heart disease and total mortality without low HDL cholesterol levels.","date":"2011","source":"Journal of internal medicine","url":"https://pubmed.ncbi.nlm.nih.gov/21443680","citation_count":33,"is_preprint":false},{"pmid":"17964293","id":"PMC_17964293","title":"Genetic association study of APOA1/C3/A4/A5 gene cluster and haplotypes on triglyceride and HDL cholesterol in a community-based population.","date":"2007","source":"Clinica chimica acta; international journal of clinical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17964293","citation_count":33,"is_preprint":false},{"pmid":"18206649","id":"PMC_18206649","title":"APOA1/C3/A5 haplotype and risk of hypertriglyceridemia in Taiwanese.","date":"2007","source":"Clinica chimica acta; international journal of clinical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18206649","citation_count":33,"is_preprint":false},{"pmid":"38018436","id":"PMC_38018436","title":"Flipped C-Terminal Ends of APOA1 Promote ABCA1-Dependent Cholesterol Efflux by Small HDLs.","date":"2023","source":"Circulation","url":"https://pubmed.ncbi.nlm.nih.gov/38018436","citation_count":32,"is_preprint":false},{"pmid":"18801202","id":"PMC_18801202","title":"Genetic studies on the APOA1-C3-A5 gene cluster in Asian Indians with premature coronary artery disease.","date":"2008","source":"Lipids in health and disease","url":"https://pubmed.ncbi.nlm.nih.gov/18801202","citation_count":32,"is_preprint":false},{"pmid":"32244181","id":"PMC_32244181","title":"ApoA-1 improves glucose tolerance by increasing glucose uptake into heart and skeletal muscle independently of AMPKα2.","date":"2020","source":"Molecular metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/32244181","citation_count":31,"is_preprint":false},{"pmid":"26388776","id":"PMC_26388776","title":"HDL/ApoA-1 infusion and ApoA-1 gene therapy in atherosclerosis.","date":"2015","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/26388776","citation_count":31,"is_preprint":false},{"pmid":"31779197","id":"PMC_31779197","title":"LCAT, ApoD, and ApoA1 Expression and Review of Cholesterol Deposition in the Cornea.","date":"2019","source":"Biomolecules","url":"https://pubmed.ncbi.nlm.nih.gov/31779197","citation_count":28,"is_preprint":false},{"pmid":"26617857","id":"PMC_26617857","title":"Genetic association of the ApoB and ApoA1 gene polymorphisms with the risk for alcohol-induced osteonecrosis of femoral head.","date":"2015","source":"International journal of clinical and experimental pathology","url":"https://pubmed.ncbi.nlm.nih.gov/26617857","citation_count":28,"is_preprint":false},{"pmid":"30328580","id":"PMC_30328580","title":"Histone Deacetylase 3 Inhibitor Suppresses Hepatitis C Virus Replication by Regulating Apo-A1 and LEAP-1 Expression.","date":"2018","source":"Virologica Sinica","url":"https://pubmed.ncbi.nlm.nih.gov/30328580","citation_count":28,"is_preprint":false},{"pmid":"29150341","id":"PMC_29150341","title":"Increased prevalence of clinical and subclinical atherosclerosis in patients with damaging mutations in ABCA1 or APOA1.","date":"2017","source":"Journal of clinical lipidology","url":"https://pubmed.ncbi.nlm.nih.gov/29150341","citation_count":27,"is_preprint":false},{"pmid":"22675253","id":"PMC_22675253","title":"Associations of polymorphisms in the apolipoprotein APOA1-C3-A5 gene cluster with acute coronary syndrome.","date":"2012","source":"Journal of biomedicine & biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/22675253","citation_count":27,"is_preprint":false},{"pmid":"24926085","id":"PMC_24926085","title":"APOA1 mRNA expression in ovarian serous carcinoma effusions is a marker of longer survival.","date":"2014","source":"American journal of clinical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/24926085","citation_count":26,"is_preprint":false},{"pmid":"32071782","id":"PMC_32071782","title":"Long noncoding RNAs APOA1-AS, IFNG-AS1, RMRP and their related biomolecules in Egyptian patients with relapsing-remitting multiple sclerosis: Relation to disease activity and patient disability.","date":"2019","source":"Journal of advanced research","url":"https://pubmed.ncbi.nlm.nih.gov/32071782","citation_count":25,"is_preprint":false},{"pmid":"15044382","id":"PMC_15044382","title":"Haplotypes in the APOA1-C3-A4-A5 gene cluster affect plasma lipids in both humans and baboons.","date":"2004","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/15044382","citation_count":25,"is_preprint":false},{"pmid":"20164363","id":"PMC_20164363","title":"APOA1 and APOA4 gene polymorphisms influence the effects of dietary fat on LDL particle size and oxidation in healthy young adults.","date":"2010","source":"The Journal of nutrition","url":"https://pubmed.ncbi.nlm.nih.gov/20164363","citation_count":24,"is_preprint":false},{"pmid":"30128915","id":"PMC_30128915","title":"Role of long non-coding RNAs expression (ANRIL, NOS3-AS, and APOA1-AS) in development of atherosclerosis in Egyptian systemic lupus erythematosus patients.","date":"2018","source":"Clinical rheumatology","url":"https://pubmed.ncbi.nlm.nih.gov/30128915","citation_count":24,"is_preprint":false},{"pmid":"25650312","id":"PMC_25650312","title":"Design and synthesis of a novel candidate compound NTI-007 targeting sodium taurocholate cotransporting polypeptide [NTCP]-APOA1-HBx-Beclin1-mediated autophagic pathway in HBV therapy.","date":"2015","source":"Bioorganic & medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25650312","citation_count":23,"is_preprint":false},{"pmid":"32681583","id":"PMC_32681583","title":"Alzheimer's disease in the gut-Major changes in the gut of 5xFAD model mice with ApoA1 as potential key player.","date":"2020","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/32681583","citation_count":23,"is_preprint":false},{"pmid":"34382908","id":"PMC_34382908","title":"LncRNA APOA1-AS facilitates proliferation and migration and represses apoptosis of VSMCs through TAF15-mediated SMAD3 mRNA stabilization.","date":"2021","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/34382908","citation_count":22,"is_preprint":false},{"pmid":"34141821","id":"PMC_34141821","title":"Targeting the Apoa1 locus for liver-directed gene therapy.","date":"2021","source":"Molecular therapy. Methods & clinical development","url":"https://pubmed.ncbi.nlm.nih.gov/34141821","citation_count":22,"is_preprint":false},{"pmid":"15962178","id":"PMC_15962178","title":"APOA1/C3/A4 gene cluster variability and lipid levels in Brazilian children.","date":"2005","source":"Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas","url":"https://pubmed.ncbi.nlm.nih.gov/15962178","citation_count":22,"is_preprint":false},{"pmid":"35479414","id":"PMC_35479414","title":"Selective activation of ABCA1/ApoA1 signaling in the V1 by magnetoelectric stimulation ameliorates depression via regulation of synaptic plasticity.","date":"2022","source":"iScience","url":"https://pubmed.ncbi.nlm.nih.gov/35479414","citation_count":22,"is_preprint":false},{"pmid":"23650622","id":"PMC_23650622","title":"In vivo tissue cholesterol efflux is reduced in carriers of a mutation in APOA1.","date":"2013","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/23650622","citation_count":22,"is_preprint":false},{"pmid":"16403951","id":"PMC_16403951","title":"APOA1-75 G to A substitution associated with severe forms of CAD, lower levels of HDL and apoA-I among northern Indians.","date":"2005","source":"Disease markers","url":"https://pubmed.ncbi.nlm.nih.gov/16403951","citation_count":22,"is_preprint":false},{"pmid":"1673288","id":"PMC_1673288","title":"Extended haplotypes and linkage disequilibrium between 11 markers at the APOA1-C3-A4 gene cluster on chromosome 11.","date":"1991","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/1673288","citation_count":22,"is_preprint":false},{"pmid":"23989729","id":"PMC_23989729","title":"Plasma lipids, genetic variants near APOA1, and the risk of infantile hypertrophic pyloric stenosis.","date":"2013","source":"JAMA","url":"https://pubmed.ncbi.nlm.nih.gov/23989729","citation_count":21,"is_preprint":false},{"pmid":"23946344","id":"PMC_23946344","title":"Vitamin E secretion by Caco-2 monolayers to APOA1, but not to HDL, is vitamer selective.","date":"2013","source":"The Journal of nutrition","url":"https://pubmed.ncbi.nlm.nih.gov/23946344","citation_count":21,"is_preprint":false},{"pmid":"24689997","id":"PMC_24689997","title":"The apoB/apoA1 ratio predicts future cardiovascular events in patients with rheumatoid arthritis.","date":"2014","source":"Scandinavian journal of rheumatology","url":"https://pubmed.ncbi.nlm.nih.gov/24689997","citation_count":20,"is_preprint":false},{"pmid":"24376512","id":"PMC_24376512","title":"Gene-gene combination effect and interactions among ABCA1, APOA1, SR-B1, and CETP polymorphisms for serum high-density lipoprotein-cholesterol in the Japanese population.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24376512","citation_count":20,"is_preprint":false},{"pmid":"22306989","id":"PMC_22306989","title":"ApoA1: mimetic peptide reverses adipocyte dysfunction in vivo and in vitro via an increase in heme oxygenase (HO-1) and Wnt10b.","date":"2012","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/22306989","citation_count":20,"is_preprint":false},{"pmid":"26200866","id":"PMC_26200866","title":"Small-angle X-ray scattering of the cholesterol incorporation into human ApoA1-POPC discoidal particles.","date":"2015","source":"Biophysical journal","url":"https://pubmed.ncbi.nlm.nih.gov/26200866","citation_count":20,"is_preprint":false},{"pmid":"22323901","id":"PMC_22323901","title":"Polymorphism in apoA1 Influences High-Density Lipoprotein Cholesterol Levels but Is Not a Major Risk Factor of Alzheimer's Disease.","date":"2012","source":"Dementia and geriatric cognitive disorders extra","url":"https://pubmed.ncbi.nlm.nih.gov/22323901","citation_count":20,"is_preprint":false},{"pmid":"15657615","id":"PMC_15657615","title":"Polymorphisms in APOA1 and LPL genes are statistically independently associated with fasting TG in men with CAD.","date":"2005","source":"European journal of human genetics : EJHG","url":"https://pubmed.ncbi.nlm.nih.gov/15657615","citation_count":20,"is_preprint":false},{"pmid":"38190128","id":"PMC_38190128","title":"FOXM1 Participates in Scleral Remodeling in Myopia by Upregulating APOA1 Expression Through METTL3/YTHDF2.","date":"2024","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/38190128","citation_count":19,"is_preprint":false},{"pmid":"22246850","id":"PMC_22246850","title":"The relationship between high-sensitivity C-reactive protein and ApoB, ApoB/ApoA1 ratio in general population of China.","date":"2012","source":"Endocrine","url":"https://pubmed.ncbi.nlm.nih.gov/22246850","citation_count":19,"is_preprint":false},{"pmid":"24508624","id":"PMC_24508624","title":"Gender-specific associations of the APOA1 -75G>A polymorphism with several metabolic syndrome components in Turkish adults.","date":"2014","source":"Clinica chimica acta; international journal of clinical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/24508624","citation_count":19,"is_preprint":false},{"pmid":"27171122","id":"PMC_27171122","title":"APOA5 and APOA1 polymorphisms are associated with triglyceride levels in Mexican children.","date":"2016","source":"Pediatric obesity","url":"https://pubmed.ncbi.nlm.nih.gov/27171122","citation_count":18,"is_preprint":false},{"pmid":"31412738","id":"PMC_31412738","title":"Serum apoA1 (Apolipoprotein A-1), Insulin Resistance, and the Risk of Gestational Diabetes Mellitus in Human Pregnancy-Brief Report.","date":"2019","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/31412738","citation_count":18,"is_preprint":false},{"pmid":"27734225","id":"PMC_27734225","title":"Increased expression of ApoA1 after neuronal injury may be beneficial for healing.","date":"2016","source":"Molecular and cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/27734225","citation_count":17,"is_preprint":false},{"pmid":"29859275","id":"PMC_29859275","title":"Role of rs670 variant of APOA1 gene on lipid profile, insulin resistance and adipokine levels in obese subjects after weight loss with a dietary intervention.","date":"2018","source":"Diabetes research and clinical practice","url":"https://pubmed.ncbi.nlm.nih.gov/29859275","citation_count":17,"is_preprint":false},{"pmid":"20488818","id":"PMC_20488818","title":"Amelioration of nephropathy with apoA-1 mimetic peptide in apoE-deficient mice.","date":"2010","source":"Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association","url":"https://pubmed.ncbi.nlm.nih.gov/20488818","citation_count":17,"is_preprint":false},{"pmid":"23829168","id":"PMC_23829168","title":"The dyslipidemia-associated SNP on the APOA1/C3/A5 gene cluster predicts post-surgery poor outcome in Taiwanese breast cancer patients: a 10-year follow-up study.","date":"2013","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/23829168","citation_count":17,"is_preprint":false},{"pmid":"17378725","id":"PMC_17378725","title":"Polymorphisms in the APOA1/C3/A4/A5 gene cluster and cholesterol responsiveness to dietary change.","date":"2007","source":"Clinical chemistry and laboratory medicine","url":"https://pubmed.ncbi.nlm.nih.gov/17378725","citation_count":16,"is_preprint":false},{"pmid":"34226567","id":"PMC_34226567","title":"High prevalence of APOA1/C3/A4/A5 alterations in luminal breast cancers among young women in East Asia.","date":"2021","source":"NPJ breast cancer","url":"https://pubmed.ncbi.nlm.nih.gov/34226567","citation_count":16,"is_preprint":false},{"pmid":"23754445","id":"PMC_23754445","title":"Controlling the diameter, monodispersity, and solubility of ApoA1 nanolipoprotein particles using telodendrimer chemistry.","date":"2013","source":"Protein science : a publication of the Protein Society","url":"https://pubmed.ncbi.nlm.nih.gov/23754445","citation_count":16,"is_preprint":false},{"pmid":"30473024","id":"PMC_30473024","title":"ApoA-1 accelerates regeneration of small-for-size fatty liver graft after transplantation.","date":"2018","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/30473024","citation_count":16,"is_preprint":false},{"pmid":"30467071","id":"PMC_30467071","title":"Role of rs670 variant of APOA1 gene on metabolic response after a high fat vs. a low fat hypocaloric diets in obese human subjects.","date":"2018","source":"Journal of diabetes and its complications","url":"https://pubmed.ncbi.nlm.nih.gov/30467071","citation_count":16,"is_preprint":false},{"pmid":"34555726","id":"PMC_34555726","title":"Hsa_circ_0088212-mediated miR-520 h/APOA1 axis inhibits osteosarcoma progression.","date":"2021","source":"Translational oncology","url":"https://pubmed.ncbi.nlm.nih.gov/34555726","citation_count":15,"is_preprint":false},{"pmid":"24081495","id":"PMC_24081495","title":"Genetic polymorphisms in the APOA1 gene and their relationship with serum HDL cholesterol levels.","date":"2013","source":"Lipids","url":"https://pubmed.ncbi.nlm.nih.gov/24081495","citation_count":15,"is_preprint":false},{"pmid":"23690001","id":"PMC_23690001","title":"Genetic association between APOA1 and APOD polymorphisms and Alzheimer's disease in a Japanese population.","date":"2013","source":"Journal of neural transmission (Vienna, Austria : 1996)","url":"https://pubmed.ncbi.nlm.nih.gov/23690001","citation_count":15,"is_preprint":false},{"pmid":"33086869","id":"PMC_33086869","title":"HDL (High-Density Lipoprotein) and ApoA-1 (Apolipoprotein A-1) Potentially Modulate Pancreatic α-Cell Glucagon Secretion.","date":"2020","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/33086869","citation_count":15,"is_preprint":false},{"pmid":"20480398","id":"PMC_20480398","title":"APOA1/A5 variants and haplotypes as a risk factor for obesity and better lipid profiles in a Brazilian Elderly Cohort.","date":"2010","source":"Lipids","url":"https://pubmed.ncbi.nlm.nih.gov/20480398","citation_count":15,"is_preprint":false},{"pmid":"28969676","id":"PMC_28969676","title":"Interactions of six SNPs in APOA1 gene and types of obesity on low HDL-C disease in Xinjiang pastoral area of China.","date":"2017","source":"Lipids in health and disease","url":"https://pubmed.ncbi.nlm.nih.gov/28969676","citation_count":15,"is_preprint":false},{"pmid":"31165758","id":"PMC_31165758","title":"Association of BUD13-ZNF259-APOA5-APOA1-SIK3 cluster polymorphism in 11q23.3 and structure of APOA5 with increased plasma triglyceride levels in a Korean population.","date":"2019","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/31165758","citation_count":15,"is_preprint":false},{"pmid":"27240838","id":"PMC_27240838","title":"A case report of hereditary apolipoprotein A-I amyloidosis associated with a novel APOA1 mutation and variable phenotype.","date":"2016","source":"European journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/27240838","citation_count":15,"is_preprint":false},{"pmid":"33244380","id":"PMC_33244380","title":"Introducing APOA1 as a key protein in COVID-19 infection: a bioinformatics approach.","date":"2020","source":"Gastroenterology and hepatology from bed to bench","url":"https://pubmed.ncbi.nlm.nih.gov/33244380","citation_count":14,"is_preprint":false},{"pmid":"15488874","id":"PMC_15488874","title":"A prospective study of the APOA1 XmnI and APOC3 SstI polymorphisms in the APOA1/C3/A4 gene cluster and risk of incident myocardial infarction in men.","date":"2004","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/15488874","citation_count":14,"is_preprint":false},{"pmid":"17727676","id":"PMC_17727676","title":"Effect of the combination of the variants -75G/A APOA1 and Trp64Arg ADRB3 on the risk of type 2 diabetes (DM2).","date":"2007","source":"Clinical endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/17727676","citation_count":14,"is_preprint":false},{"pmid":"25463085","id":"PMC_25463085","title":"Tissue-specific DNA methylation profiles regulate liver-specific expression of the APOA1/C3/A4/A5 cluster and can be manipulated with demethylating agents on intestinal cells.","date":"2014","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/25463085","citation_count":13,"is_preprint":false},{"pmid":"29747660","id":"PMC_29747660","title":"Association of the APOA1 rs964184 SNP and serum lipid traits in the Chinese Maonan and Han populations.","date":"2018","source":"Lipids in health and disease","url":"https://pubmed.ncbi.nlm.nih.gov/29747660","citation_count":13,"is_preprint":false},{"pmid":"16309370","id":"PMC_16309370","title":"APOA1 polymorphisms are associated with variations in serum triglyceride concentrations in hypercholesterolemic individuals.","date":"2005","source":"Clinical chemistry and laboratory medicine","url":"https://pubmed.ncbi.nlm.nih.gov/16309370","citation_count":13,"is_preprint":false},{"pmid":"27105909","id":"PMC_27105909","title":"Heparin interactions with apoA1 and SAA in inflammation-associated HDL.","date":"2016","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/27105909","citation_count":12,"is_preprint":false},{"pmid":"30004304","id":"PMC_30004304","title":"High Level of APOA1 in Blood and Maternal Fetal Interface Is Associated With Early Miscarriage.","date":"2018","source":"Reproductive sciences (Thousand Oaks, Calif.)","url":"https://pubmed.ncbi.nlm.nih.gov/30004304","citation_count":12,"is_preprint":false},{"pmid":"30631647","id":"PMC_30631647","title":"Functional polymorphisms of the APOA1/C3/A4/A5-ZPR1-BUD13 gene cluster are associated with dyslipidemia in a sex-specific pattern.","date":"2019","source":"PeerJ","url":"https://pubmed.ncbi.nlm.nih.gov/30631647","citation_count":12,"is_preprint":false},{"pmid":"21576418","id":"PMC_21576418","title":"Comparison of lipid profiles with APOA1 MspI polymorphism in obese children with hyperlipidemia.","date":"2011","source":"In vivo (Athens, Greece)","url":"https://pubmed.ncbi.nlm.nih.gov/21576418","citation_count":12,"is_preprint":false},{"pmid":"2108924","id":"PMC_2108924","title":"Apolipoprotein A1 Baltimore (Arg10----Leu), a new ApoA1 variant.","date":"1990","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/2108924","citation_count":12,"is_preprint":false},{"pmid":"35858961","id":"PMC_35858961","title":"APOA1 mRNA and protein in kidney renal clear cell carcinoma correlate with the disease outcome.","date":"2022","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/35858961","citation_count":11,"is_preprint":false},{"pmid":"33358712","id":"PMC_33358712","title":"The loss-of-function mutation of CETP affects HDLc levels but not ApoA1 in patients with acute myocardial infarction.","date":"2020","source":"Nutrition, metabolism, and cardiovascular diseases : NMCD","url":"https://pubmed.ncbi.nlm.nih.gov/33358712","citation_count":11,"is_preprint":false},{"pmid":"29968409","id":"PMC_29968409","title":"Two novel APOA1 gene mutations in a Japanese renal transplant recipient with recurrent apolipoprotein A-I related amyloidosis.","date":"2018","source":"Nephrology (Carlton, Vic.)","url":"https://pubmed.ncbi.nlm.nih.gov/29968409","citation_count":11,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":56563,"output_tokens":4830,"usd":0.121069,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":13069,"output_tokens":3676,"usd":0.078622,"stage2_stop_reason":"end_turn"},"total_usd":0.199691,"stage1_batch_id":"msgbatch_0179Z2pxRYBsXi2xADneafRw","stage2_batch_id":"msgbatch_01LaY9ZaVdgjWArcZo9eqQE5","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2018,\n      \"finding\": \"APOA1 on nascent discoidal HDL adopts two distinct helical registries (5/5 and 5/2) via a thumbwheel-like rotation mechanism. Engineered disulfide bonds locking APOA1 in the 5/2 registry impaired LCAT cholesteryl esterification activity without affecting LCAT binding or cholesterol efflux, indicating that full LCAT activation requires a hybrid epitope composed of helices 5-7 on one APOA1 molecule and helices 3-4 on the other.\",\n      \"method\": \"Cysteine mutagenesis to engineer disulfide-locked discoidal HDL particles, LCAT activity assay, cholesterol efflux assay, chemical cross-linking\",\n      \"journal\": \"Journal of lipid research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — reconstitution with mutagenesis, disulfide-locking, enzymatic activity assay, and cross-linking in a single rigorous study with multiple orthogonal methods\",\n      \"pmids\": [\"29773713\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"In small HDL particles, the C-termini of the two antiparallel APOA1 molecules are 'flipped' off the lipid surface, enabling engagement with ABCA1 transporter and promoting cholesterol efflux. In larger HDL particles, C-termini form a helical bundle adhering to the lipid surface, preventing productive ABCA1 interaction. Conversion of small HDL to larger particles by LCAT markedly inhibited cholesterol efflux capacity.\",\n      \"method\": \"Tandem mass spectrometric analysis of chemically cross-linked peptides, molecular dynamics simulations, reconstituted HDL model system, cholesterol efflux capacity assay in macrophages, studies in LCAT-deficient subjects, calibrated ion mobility analysis\",\n      \"journal\": \"Circulation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — multiple orthogonal methods including MS cross-linking, MD simulation, reconstituted HDL, and human disease model with mechanistic validation\",\n      \"pmids\": [\"38018436\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"TRIM15 E3 ubiquitin ligase interacts with APOA1 through its PRY/SPRY domain and promotes APOA1 polyubiquitination via its RING domain, leading to APOA1 degradation. APOA1 degradation enhances lipid anabolism and promotes lipid droplet accumulation in pancreatic cancer cells, and TRIM15 promotes PDAC metastasis via the APOA1-LDLR axis.\",\n      \"method\": \"Mass spectrometry identification of TRIM15-binding partners, co-immunoprecipitation, domain-deletion mutagenesis, ubiquitination assay, siRNA knockdown with invasion/migration assays, lipid droplet staining\",\n      \"journal\": \"Biochimica et biophysica acta. Molecular basis of disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP, domain mutagenesis, and ubiquitination assay from single lab with multiple methods\",\n      \"pmids\": [\"34311082\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"In vivo tissue cholesterol efflux is reduced by ~19% in carriers of the L202P mutation in APOA1 (mean HDL-c 20 mg/dL vs. 54 mg/dL in controls), demonstrating that APOA1 contributes to efflux of tissue cholesterol in humans as part of reverse cholesterol transport. Fecal sterol excretion did not differ significantly, suggesting non-HDL pathways also contribute to reverse cholesterol transport.\",\n      \"method\": \"13C2-cholesterol isotope tracer infusion in vivo, three-compartment SAAM-II pharmacokinetic modeling, fecal 13C recovery measurement in APOA1 L202P mutation carriers vs. controls\",\n      \"journal\": \"Journal of lipid research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct in vivo isotope tracer study in human mutation carriers with compartmental modeling, single lab\",\n      \"pmids\": [\"23650622\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Recombinant ApoA-1 injected in vivo improves glucose tolerance and increases glucose clearance into skeletal muscle (+50%) and heart muscle (+270%) independently of AMPKα2 kinase activity. ApoA-1 also increased glucose-stimulated insulin secretion. ApoA-1 failed to increase glucose uptake in isolated skeletal muscles ex vivo, indicating that systemic effects beyond direct muscle action are required.\",\n      \"method\": \"Intravenous injection of recombinant human ApoA-1 in high-fat diet-fed wild-type and AMPKα2 kinase-dead mice, glucose tolerance test, 2-deoxyglucose uptake measurement in vivo, epinephrine/propranolol-induced insulin secretion blockade, ex vivo isolated muscle glucose uptake assay\",\n      \"journal\": \"Molecular metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — clean genetic KO model (AMPKα2 kinase-dead) with defined metabolic phenotype and multiple conditions tested, single lab\",\n      \"pmids\": [\"32244181\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"ApoA1-mediated lipid raft depletion inhibits DENV (dengue virus) attachment to cell surfaces. ApoA1 neutralizes NS1-induced cell activation and prevents NS1-mediated enhancement of DENV infection. The ApoA1 mimetic peptide 4F similarly depletes lipid rafts to control DENV infection.\",\n      \"method\": \"Cell-based infection assay, lipid raft staining/quantification, NS1 protein treatment of cells, ApoA1 co-treatment, peptide 4F treatment, flow cytometry\",\n      \"journal\": \"Journal of virology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct cell-based mechanistic experiments with protein-virus interaction and multiple readouts from single lab\",\n      \"pmids\": [\"33827950\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"In an in vitro BBB model, rApoA1 complexed to Aβ1-40 did not influence Aβ1-40 efflux from the basolateral (brain) compartment, but rApoA1 present in the apical (blood) compartment mobilized Aβ1-40 from the basolateral side. rApoA1 crossed the monolayer (blood-to-brain direction) through a mechanism involving the LDL receptor-related protein family, and rApoA1 trafficking was restricted when bound to Aβ peptide.\",\n      \"method\": \"Primary cerebral endothelial cell Transwell BBB model, fluorescently labeled Aβ1-40 transport assay, LRP family inhibitor treatment, compartment-specific protein addition\",\n      \"journal\": \"Journal of Alzheimer's disease : JAD\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, in vitro model only, no molecular mechanistic follow-up beyond transport measurement\",\n      \"pmids\": [\"27232214\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"SAXS structural analysis showed that in discoidal ApoA1-POPC-cholesterol particles, the N-terminal domain of full-length ApoA1 is an integrated part of the protein belt (not a separate globular domain) that stabilizes the particles. Upon cholesterol incorporation, the N-terminal domain allows bilayer thickness to increase while maintaining a flat bilayer, in contrast to N-terminally truncated ApoA1 (nanodisc) which forms a less favorable lens shape.\",\n      \"method\": \"Small-angle X-ray scattering (SAXS), molecular-constrained data modeling, comparison of full-length vs. N-terminally truncated ApoA1 particles with varying cholesterol content\",\n      \"journal\": \"Biophysical journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — SAXS structural analysis with molecular modeling and comparative functional context, single lab\",\n      \"pmids\": [\"26200866\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"HDL and ApoA-1 reduce glucagon expression and secretion from pancreatic α-cells in vitro through binding to receptor SCARB-1 (SR-BI) and activating the PI3K/Akt/FoxO1 signaling cascade. Pretreatment with Akt inhibitor, PI3K inhibitor, or SCARB-1 inhibitor BLT-1 restored α-cell response to low glucose, demonstrating dependence on this pathway.\",\n      \"method\": \"In vitro αTC1 cell treatment with HDL or ApoA-1, glucagon secretion and expression assays, phosphorylation assays for Akt and FoxO1, pharmacological inhibitors (Akt inhibitor VIII, LY294002, BLT-1), in vivo mouse ApoA-1 injection with insulin-induced hypoglycemia\",\n      \"journal\": \"Arteriosclerosis, thrombosis, and vascular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple pathway inhibitors used in cell-based assay plus in vivo validation, single lab\",\n      \"pmids\": [\"33086869\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"ApoA1 activates the ERK pathway and promotes actin polymerization in a neuroblastoma injury model, contributing to wound healing after neuronal injury. ApoA1 expression increases as a delayed response to neuronal injury, and ApoA1 treatment accelerated scratch wound closure after an initial lag phase.\",\n      \"method\": \"Neuroblastoma scratch wound assay, ApoA1 treatment, ERK pathway activation measurement, actin polymerization assay, spinal cord injury model\",\n      \"journal\": \"Molecular and cellular biochemistry\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, limited mechanistic detail in abstract, single cell-type model\",\n      \"pmids\": [\"27734225\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"ApoA-1 treatment of hepatocytes attenuated steatosis and accelerated proliferation, and in a mouse hepatectomy model promoted liver regeneration at day 2 post-surgery. ApoA-1 treatment increased expression of PGC-1α and its target genes Tfam, Ucp2, and SDHB, suggesting a mechanism through regulation of mitochondrial function.\",\n      \"method\": \"Rat liver transplantation model (small-for-size fatty graft), mouse hepatectomy model in vivo, in vitro hepatocyte culture with ApoA-1 treatment, gene expression analysis (PGC-1α, Tfam, Ucp2, SDHB), steatosis quantification\",\n      \"journal\": \"Life sciences\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, mechanistic pathway identified by expression analysis only without direct functional validation of PGC-1α pathway dependence\",\n      \"pmids\": [\"30473024\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Heparin interacts with both ApoA1 and SAA (serum amyloid A) on HDL isolated from inflamed mice, forming complex aggregates. Mass spectrometry analysis of chemically crosslinked HDL-SAA particles detected multiple crosslinks between ApoA1 and SAA, indicating close proximity (within 25 Å) on the HDL surface, providing a structural basis for simultaneous heparin binding.\",\n      \"method\": \"Gel electrophoresis of heparin-HDL complexes, chemical crosslinking, mass spectrometry peptide mapping of crosslinked ApoA1-SAA interactions\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, crosslinking-MS provides proximity data but no direct functional consequence tested\",\n      \"pmids\": [\"27105909\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"ABCA1-dependent secretion of vitamin E (tocopherols) from Caco-2 intestinal monolayers is mediated in part via ApoA1 as acceptor. The ABCA1/ApoA1 pathway demonstrated vitamer selectivity, with α- and γ-tocopherol secreted more efficiently than δ-tocopherol. Liver X receptor agonist T0901317 induced ABCA1 expression and enhanced tocopherol secretion to ApoA1.\",\n      \"method\": \"Polarized Caco-2 monolayer assay, ABCA1 protein expression (Western blot), LXR agonist treatment, MTP inhibitor treatment, tocopherol secretion quantification with three tocopherol forms simultaneously\",\n      \"journal\": \"The Journal of nutrition\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mechanistic dissection using pharmacological tools with multiple tocopherol forms and ABCA1 expression data, single lab\",\n      \"pmids\": [\"23946344\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Tissue-specific DNA methylation of the APOA1/C3/A4/A5 gene cluster inversely correlates with tissue-specific expression. APOA1 promoter is less methylated in liver than other tissues. Demethylation of intestinal TC7/Caco-2 cells with 5-Aza-2'-deoxycytidine reduced methylation of APOA1/C3/A4/A5 by 24-37% and induced re-expression of APOA1 mRNA (up to 600% increase), demonstrating that DNA methylation controls liver-specific APOA1 expression.\",\n      \"method\": \"Infinium HumanMethylation450 BeadChip array across multiple tissues, bisulfite PCR and pyrosequencing, 5-Aza-2'-deoxycytidine demethylation treatment of intestinal cells, RT-qPCR for gene re-expression\",\n      \"journal\": \"Atherosclerosis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genome-wide methylation profiling validated by bisulfite sequencing, combined with functional demethylation rescue experiment, single lab\",\n      \"pmids\": [\"25463085\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"FOXM1 transcription factor represses METTL3 transcription by binding to the METTL3 promoter (confirmed by ChIP), which reduces m6A methylation of APOA1 mRNA, thereby decreasing YTHDF2-mediated APOA1 mRNA degradation and increasing APOA1 expression. Elevated APOA1 in hypoxia-induced scleral fibroblasts promotes myofibroblast transdifferentiation, reduced collagen production, and apoptosis. Knockdown of APOA1 or FOXM1 reversed these hypoxia-induced effects.\",\n      \"method\": \"Chromatin immunoprecipitation (ChIP) for FOXM1 on METTL3 promoter, methylated RNA immunoprecipitation (Me-RIP) for m6A on APOA1 mRNA, PAR-CLIP for METTL3-APOA1 binding, siRNA knockdown, Western blot, RT-qPCR, cell proliferation/apoptosis assays\",\n      \"journal\": \"Investigative ophthalmology & visual science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal epigenetic methods (ChIP, Me-RIP, PAR-CLIP) with functional rescue experiments, single lab\",\n      \"pmids\": [\"38190128\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Denaturation and fusion kinetics of discoidal HDL particles show that kinetic stability rank order is apoA-1 > apoA-2 > apoC-1, correlating with protein size. Protein unfolding triggers HDL fusion, leading to lipid vesicle formation and dissociation of monomolecular lipid-poor protein. Two kinetic phases with distinct activation energies (Ea,slow = 60 kcal/mol, Ea,fast = 22 kcal/mol) were identified for apoA-2 disks.\",\n      \"method\": \"Circular dichroism melting, light scattering, differential scanning calorimetry, Arrhenius analysis, electron microscopy, gel electrophoresis; comparative analysis of apoA-1 vs apoA-2 vs apoC-1 disks\",\n      \"journal\": \"Biophysical journal\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — comparative biophysical study primarily focused on apoA-2; APOA1 data are comparative reference points, not the primary subject of mechanistic analysis\",\n      \"pmids\": [\"15681655\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"APOA1 is the major structural and functional protein of HDL that adopts anti-parallel helical ring configurations on discoidal HDL particles, with the two molecules capable of adopting distinct registries (5/5 vs 5/2) via a thumbwheel mechanism to activate LCAT; in small HDL particles the C-termini flip off the lipid surface to engage ABCA1 and drive cholesterol efflux, while on larger particles the C-termini form a helical bundle that prevents ABCA1 interaction; APOA1 mediates reverse cholesterol transport in vivo (established by isotope tracer studies in mutation carriers), activates glucagon suppression in pancreatic α-cells via SCARB-1/PI3K/Akt/FoxO1, promotes glucose uptake in muscle independently of AMPKα2, is subject to ubiquitin-mediated degradation by TRIM15, and its expression is regulated by tissue-specific DNA methylation and by the FOXM1-METTL3-m6A-YTHDF2 axis.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"APOA1 is the principal structural and functional protein of HDL, organizing lipid particles and driving reverse cholesterol transport [#0, #3]. On nascent discoidal HDL the two antiparallel APOA1 molecules adopt distinct helical registries (5/5 and 5/2) interconverting via a thumbwheel-like rotation; full activation of LCAT-mediated cholesteryl esterification requires a hybrid epitope formed by helices 5\\u20137 of one molecule and helices 3\\u20134 of the other [#0]. The integrated N-terminal domain functions as part of the protein belt that stabilizes the discoidal bilayer and accommodates cholesterol loading [#7]. Particle size governs function: in small HDL the APOA1 C-termini flip off the lipid surface to engage the ABCA1 transporter and promote cholesterol efflux, whereas in larger particles the C-termini form a lipid-adherent helical bundle that prevents productive ABCA1 interaction, so LCAT-driven conversion of small to large HDL suppresses efflux capacity [#1]. The ABCA1/APOA1 acceptor system also mediates selective tocopherol secretion from intestinal cells [#12]. In humans, the APOA1 L202P mutation reduces in vivo tissue cholesterol efflux, confirming a causal contribution to reverse cholesterol transport [#3]. Beyond lipid handling, APOA1 acts as a signaling ligand: it engages SCARB-1 to activate PI3K/Akt/FoxO1 and suppress glucagon in pancreatic \\u03b1-cells [#8] and improves systemic glucose tolerance and muscle glucose uptake independently of AMPK\\u03b12 [#4]. APOA1 abundance is controlled both by tissue-specific promoter DNA methylation favoring hepatic expression [#13] and by the FOXM1\\u2013METTL3\\u2013m6A\\u2013YTHDF2 axis governing mRNA stability [#14], and the protein is targeted for polyubiquitination and degradation by the E3 ligase TRIM15 [#2].\",\n  \"teleology\": [\n    {\n      \"year\": 2005,\n      \"claim\": \"Established the relative kinetic stability of APOA1 on discoidal particles and linked protein unfolding to HDL fusion and lipid-poor protein release, framing HDL remodeling as a kinetically governed process.\",\n      \"evidence\": \"Comparative biophysical analysis (CD melting, DSC, light scattering, EM) of apoA-1 vs apoA-2 vs apoC-1 disks\",\n      \"pmids\": [\"15681655\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"APOA1 served as a comparative reference, not the primary subject\", \"No connection to physiological remodeling enzymes tested\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Provided direct in vivo human evidence that APOA1 drives tissue cholesterol efflux, moving reverse cholesterol transport from inference to causal demonstration.\",\n      \"evidence\": \"13C-cholesterol isotope tracer infusion with compartmental modeling in APOA1 L202P mutation carriers vs controls\",\n      \"pmids\": [\"23650622\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Fecal sterol excretion unchanged, indicating non-HDL pathways contribute\", \"Single mutation, single lab\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Resolved the structural role of the APOA1 N-terminal domain, showing it is integrated into the lipid-binding belt rather than a separate globular module and enables stable cholesterol-loaded discs.\",\n      \"evidence\": \"SAXS with molecular modeling comparing full-length vs N-terminally truncated APOA1 particles at varying cholesterol\",\n      \"pmids\": [\"26200866\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No atomic-resolution structure\", \"Does not address dynamics during enzymatic remodeling\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Defined the conformational mechanism of LCAT activation, showing APOA1 toggles between helical registries and that a two-molecule hybrid epitope is required for esterification activity.\",\n      \"evidence\": \"Disulfide-locked discoidal HDL via cysteine mutagenesis, LCAT activity and efflux assays, chemical cross-linking\",\n      \"pmids\": [\"29773713\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Registry switching kinetics in native particles not measured\", \"Triggers of the thumbwheel rotation in vivo unknown\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Linked HDL particle size to cholesterol efflux capacity through C-terminal positioning, explaining why LCAT-driven particle enlargement suppresses ABCA1 engagement.\",\n      \"evidence\": \"Cross-linking MS, MD simulation, reconstituted HDL, macrophage efflux assays, LCAT-deficient human subjects\",\n      \"pmids\": [\"38018436\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structure of the APOA1\\u2013ABCA1 contact not solved\", \"Regulation of C-terminal flipping in vivo not defined\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Showed the ABCA1/APOA1 acceptor pathway exports cargo beyond cholesterol, mediating vitamer-selective tocopherol secretion from intestinal cells.\",\n      \"evidence\": \"Polarized Caco-2 monolayer secretion assay with LXR agonist and MTP inhibitor, ABCA1 Western blot\",\n      \"pmids\": [\"23946344\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular basis of vitamer selectivity unresolved\", \"In vivo relevance not tested\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Identified APOA1 as a glucose-homeostasis signaling ligand, suppressing glucagon via SCARB-1/PI3K/Akt/FoxO1 and enhancing muscle glucose uptake through systemic rather than direct mechanisms.\",\n      \"evidence\": \"\\u03b1TC1 cell assays with pathway inhibitors plus in vivo mouse injection (glucagon study); recombinant ApoA-1 injection in HFD and AMPK\\u03b12 kinase-dead mice with 2-DG uptake (glucose study)\",\n      \"pmids\": [\"33086869\", \"32244181\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Receptor mediating muscle effect not identified\", \"Failure of ex vivo muscle uptake leaves systemic mediator undefined\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Revealed post-translational control of APOA1 abundance, with TRIM15 binding via its PRY/SPRY domain and polyubiquitinating APOA1 via its RING domain to drive degradation and tumor lipid accumulation.\",\n      \"evidence\": \"MS interactor identification, reciprocal Co-IP, domain-deletion mutagenesis, ubiquitination assay, knockdown invasion assays in PDAC cells\",\n      \"pmids\": [\"34311082\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Ubiquitination sites on APOA1 not mapped\", \"Single lab, cancer-context only\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Established that tissue-specific DNA methylation of the APOA1/C3/A4/A5 cluster controls hepatic-restricted APOA1 expression.\",\n      \"evidence\": \"Genome-wide methylation array, bisulfite pyrosequencing, 5-Aza demethylation rescue with RT-qPCR re-expression\",\n      \"pmids\": [\"25463085\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Specific regulatory CpGs not functionally dissected\", \"Trans-acting factors reading methylation not identified\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Defined an epitranscriptomic regulatory axis in which FOXM1 represses METTL3 to lower APOA1 m6A marking, reducing YTHDF2-mediated mRNA decay and raising APOA1 with downstream effects on scleral fibroblast fate.\",\n      \"evidence\": \"ChIP, Me-RIP, PAR-CLIP, siRNA knockdown with rescue, RT-qPCR and apoptosis assays in hypoxic scleral fibroblasts\",\n      \"pmids\": [\"38190128\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"m6A sites on APOA1 mRNA not precisely mapped\", \"Generalizability beyond scleral fibroblasts untested\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How the registry/thumbwheel conformational cycle, C-terminal flipping, and size-dependent ABCA1 engagement are coordinated and regulated on native circulating HDL remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No native high-resolution structure of the APOA1\\u2013ABCA1 complex\", \"Physiological triggers of conformational switching unknown\", \"Integration of transcriptional, epitranscriptomic, and degradation control into systemic lipid/glucose phenotypes not established\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0008289\", \"supporting_discovery_ids\": [0, 1, 7]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [0, 8]},\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [8, 4]},\n      {\"term_id\": \"GO:0005198\", \"supporting_discovery_ids\": [1, 7]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [0, 1, 3]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [0, 1, 3, 12]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [8, 4]},\n      {\"term_id\": \"R-HSA-382551\", \"supporting_discovery_ids\": [1, 12]}\n    ],\n    \"complexes\": [\"HDL\"],\n    \"partners\": [\"LCAT\", \"ABCA1\", \"SCARB1\", \"TRIM15\", \"SAA\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":8,"faith_total":8,"faith_pct":100.0}}